CA3229044A1 - Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same - Google Patents

Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same Download PDF

Info

Publication number
CA3229044A1
CA3229044A1 CA3229044A CA3229044A CA3229044A1 CA 3229044 A1 CA3229044 A1 CA 3229044A1 CA 3229044 A CA3229044 A CA 3229044A CA 3229044 A CA3229044 A CA 3229044A CA 3229044 A1 CA3229044 A1 CA 3229044A1
Authority
CA
Canada
Prior art keywords
ch2ch3
och3
cyclopropyl
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3229044A
Other languages
English (en)
French (fr)
Inventor
David Gilles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuleon LLC
Original Assignee
Kuleon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuleon LLC filed Critical Kuleon LLC
Publication of CA3229044A1 publication Critical patent/CA3229044A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3229044A 2021-08-12 2022-08-11 Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same Pending CA3229044A1 (en)

Applications Claiming Priority (41)

Application Number Priority Date Filing Date Title
US202163232614P 2021-08-12 2021-08-12
US202163232548P 2021-08-12 2021-08-12
US202163232539P 2021-08-12 2021-08-12
US63/232,548 2021-08-12
US63/232,539 2021-08-12
US63/232,614 2021-08-12
US202163238133P 2021-08-28 2021-08-28
US202163238135P 2021-08-28 2021-08-28
US202163238134P 2021-08-28 2021-08-28
US202163238132P 2021-08-28 2021-08-28
US63/238,133 2021-08-28
US63/238,134 2021-08-28
US63/238,132 2021-08-28
US63/238,135 2021-08-28
US202163239965P 2021-09-02 2021-09-02
US202163239963P 2021-09-02 2021-09-02
US202163239964P 2021-09-02 2021-09-02
US63/239,963 2021-09-02
US63/239,965 2021-09-02
US63/239,964 2021-09-02
US202163285656P 2021-12-03 2021-12-03
US202163285688P 2021-12-03 2021-12-03
US202163285679P 2021-12-03 2021-12-03
US63/285,688 2021-12-03
US63/285,656 2021-12-03
US63/285,679 2021-12-03
US202163292567P 2021-12-22 2021-12-22
US63/292,567 2021-12-22
US202263301196P 2022-01-20 2022-01-20
US63/301,196 2022-01-20
US202263314378P 2022-02-26 2022-02-26
US202263314377P 2022-02-26 2022-02-26
US202263314379P 2022-02-26 2022-02-26
US63/314,379 2022-02-26
US63/314,378 2022-02-26
US63/314,377 2022-02-26
US202263319200P 2022-03-11 2022-03-11
US63/319,200 2022-03-11
US202263325515P 2022-03-30 2022-03-30
US63/325,515 2022-03-30
PCT/US2022/040048 WO2023018864A1 (en) 2021-08-12 2022-08-11 Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3229044A1 true CA3229044A1 (en) 2023-02-16

Family

ID=85201052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3229044A Pending CA3229044A1 (en) 2021-08-12 2022-08-11 Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same

Country Status (8)

Country Link
US (8) US11780807B2 (cg-RX-API-DMAC7.html)
EP (1) EP4384172A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531229A (cg-RX-API-DMAC7.html)
KR (1) KR20240058859A (cg-RX-API-DMAC7.html)
AU (1) AU2022328217A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229044A1 (cg-RX-API-DMAC7.html)
IL (1) IL310378A (cg-RX-API-DMAC7.html)
WO (1) WO2023018864A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
WO2022246554A1 (en) * 2021-05-26 2022-12-01 Bright Minds Biosciences Inc. Heterocyclic compounds and methods of preparation thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
JP2025501141A (ja) 2021-12-24 2025-01-17 サイロ プロプリエタリー リミテッド 化合物
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
AU2023235712A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
JP2026515993A (ja) * 2023-05-04 2026-05-19 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド 新規エルゴリン及び気分障害を処置する方法
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
JP2026524104A (ja) 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
WO2025042885A1 (en) * 2023-08-21 2025-02-27 Kuleon Llc Salts and solid forms of benzothiophene and benzoselenophene serotonin receptor modulators
WO2025049510A1 (en) * 2023-08-29 2025-03-06 Caamtech, Inc. 4-hydroxy-n-ethyltryptamine
WO2025122513A1 (en) * 2023-12-04 2025-06-12 Delix Therapeutics, Inc. Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines
WO2026137050A1 (en) * 2024-12-24 2026-07-02 Psylo Pty Ltd Compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636218A (en) 1969-10-22 1972-01-18 Colgate Palmolive Co Pharmaceutical compositions and methods containing 1 2 3 4-tetrahydrobenzothieno(2 3-c)pyridines
US4137414A (en) 1977-09-26 1979-01-30 G. D. Searle & Co. 5-Substituted-2-phenylbenzo[b]thiophene-3-alkylamines and related compounds
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9221761D0 (en) 1992-10-16 1992-12-02 Glaxo Group Ltd Chemical compounds
JPH09510216A (ja) 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
US7276603B2 (en) * 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
WO2007149728A2 (en) 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2762472B1 (en) 2011-09-28 2017-05-24 Industry-Academia Cooperation Group of Sejong University Selenophene-fused aromatic compound and manufacturing method thereof
WO2014018888A1 (en) * 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP3519816A4 (en) * 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
JP7273731B2 (ja) * 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021041407A1 (en) 2019-08-25 2021-03-04 Caamtech Llc Alkyl quarternary ammonium tryptamines and their therapeutic uses
KR102966320B1 (ko) 2019-12-20 2026-05-19 보에 테크놀로지 그룹 컴퍼니 리미티드 추론 연산 장치, 모델 훈련 장치, 및 추론 연산 시스템
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
JP2023530665A (ja) 2020-06-10 2023-07-19 デリックス セラピューティクス，インク． イソトリプタミンサイコプラストゲンおよびその使用
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022120181A1 (en) 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
WO2022246554A1 (en) 2021-05-26 2022-12-01 Bright Minds Biosciences Inc. Heterocyclic compounds and methods of preparation thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
US20250051276A1 (en) 2021-12-15 2025-02-13 Delix Therapeutics, Inc. Aryloxy psychoplastogens and uses thereof
WO2023122135A1 (en) 2021-12-22 2023-06-29 Kuleon Llc Serotonin receptor agonists and methods of making and using the same
JP2025501141A (ja) 2021-12-24 2025-01-17 サイロ プロプリエタリー リミテッド 化合物
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
AU2023323907A1 (en) * 2022-08-11 2025-02-20 Gilgamesh Pharmaceuticals, Inc. Tryptamines and methods of treating mood disorders
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
WO2025042884A2 (en) * 2023-08-21 2025-02-27 Kuleon Llc Serotonin receptor modulators for the treatment of addictions and overdoses
WO2025042885A1 (en) * 2023-08-21 2025-02-27 Kuleon Llc Salts and solid forms of benzothiophene and benzoselenophene serotonin receptor modulators

Also Published As

Publication number Publication date
US20240343690A1 (en) 2024-10-17
KR20240058859A (ko) 2024-05-03
US20240124397A1 (en) 2024-04-18
US20250282722A1 (en) 2025-09-11
US12187678B2 (en) 2025-01-07
WO2023018864A1 (en) 2023-02-16
US11780807B2 (en) 2023-10-10
US20240190819A1 (en) 2024-06-13
US12441683B2 (en) 2025-10-14
AU2022328217A1 (en) 2024-03-14
US12012380B1 (en) 2024-06-18
US20250340513A1 (en) 2025-11-06
US20250091991A1 (en) 2025-03-20
US12275701B2 (en) 2025-04-15
EP4384172A4 (en) 2025-07-30
IL310378A (en) 2024-03-01
US12344582B2 (en) 2025-07-01
US20230257346A1 (en) 2023-08-17
US20260092034A1 (en) 2026-04-02
EP4384172A1 (en) 2024-06-19
US12668574B2 (en) 2026-06-30
JP2024531229A (ja) 2024-08-29

Similar Documents

Publication Publication Date Title
US12275701B2 (en) Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators
WO2023122135A1 (en) Serotonin receptor agonists and methods of making and using the same
WO2023122320A1 (en) Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
WO2023059546A1 (en) Serotonin receptor agonists and methods of making and using the same
WO2023023298A1 (en) Hallucinogenic and non-hallucinogenic compounds and methods of making and using the same
WO2019099745A1 (en) Compositions comprising a psilocybin derivative and a cannabinoid
US20250289817A1 (en) Serotonin receptor modulators and methods of making and using the same
BR112019016489A2 (pt) composições e métodos compreendendo um derivado da psilocibina
CN109952301B (zh) 5-ht2c受体激动剂和组合物及使用方法
JP2004527500A (ja) 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンｅとｇａｂａａ逆アゴニストの併用
CN108137508A (zh) 5-ht2c受体激动剂和组合物及使用方法
US9023788B2 (en) Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
WO2025042884A2 (en) Serotonin receptor modulators for the treatment of addictions and overdoses
WO2024215824A1 (en) Serotonin receptor modulators and methods of making and using the same
WO2025117491A1 (en) Azepino analogs and methods of making and using the same
US12570602B2 (en) Selective serotonin receptor modulators and methods of making and using the same
CN118055766A (zh) 致幻性和非致幻性血清素受体激动剂及其制备和使用方法
WO2023225043A1 (en) Tricyclic and tetracyclic serotonin receptor modulators and methods of making and using the same
US9265774B2 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240729

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241126

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260427

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601